Marshall University School of Pharmacy has joined the RAPID Alliance Medications 360 Study, which aims to transform how medications and vaccines are delivered in the United States. The RAPID Alliance is a multi-stakeholder research consortium founded in the University of Louisville (UofL) Center for Health Organization Transformation (CHOT), a National Science Foundation-funded research center.
Marshall’s School of Pharmacy will help lead an all-hands-on-deck effort to co-create the RAPID Alliance Medications 360 Framework, a set of transformational strategies and a nationally prioritized research agenda for optimizing the use of medications, vaccinations and other therapies from 2022-2031.
This project is building on a 2020 research study, conducted by UofL researchers during the COVID-19 pandemic, that identified strategic opportunities to improve health and wellbeing for tens of millions of people while reducing US spending on likely-avoidable hospitalizations, emergency department and doctor visits by as much as $528 billion dollars.
“We are delighted to be part of this important national effort to co-create new, actionable strategies and research priorities to optimize medication and vaccine use for U.S. populations,” Brittany Riley, Pharm.D., associate professor at Marshall University School of Pharmacy and Marshall’s lead on the Medications 360 Study.
Marshall will contribute to this effort by supporting research and action in areas including state-level strategies for West Virginia. Marshall will additionally support special study sections on topics including rural health care and substance use disorders. More than three dozen other universities, such as the University of Cincinnati, University of Kentucky, University of Pittsburgh and the University Of South Carolina, are participating in this project.
Additional information is available at http://meds360.starstudy.link/.